Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index; none of the 11 sources its claims cite is checked for support yet.

Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values

Open access

Abstract

Aims: Many new mobile technologies are available to assist people in managing chronic conditions, but data on the association between the use of these technologies and medical spending remains limited. As the available digital technology offerings to aid in diabetes management increase, it is important to understand their impact on medical spending. The aim of this study was to investigate the financial impact of a remote digital diabetes management program using medical claims and real-time blood glucose data. Materials and methods: A retrospective analysis of multivariate difference-in-difference and instrumental variables regression modeling was performed using data collected from a remote digital diabetes management program. All employees with diabetes were invited, in a phased introduction, to join the program. Data included blood glucose (BG) values captured remotely from members via connected BG meters and medical spending claims. Participants included members (those who accepted the invitation, n = 2,261) and non-members (n = 8,741) who received health insurance benefits from three self-insured employers. Medical spending was compared between people with well-controlled (BG ≤ 154 mg/dL) and poorly controlled (BG > 154 mg/dL) diabetes. Results: Program access was associated with a 21.9% (p < 0.01) decrease in medical spending, which translates into a $88 saving per member per month at 1 year. Compared to non-members, members experienced a 10.7% (p < 0.01) reduction in diabetes-related medical spending and a 24.6% (p < 0.01) reduction in spending on office-based services. Well-controlled BG values were associated with 21.4% (p = 0.03) lower medical spending. Limitations and conclusions: Remote digital diabetes management is associated with decreased medical spending at 1 year. Reductions in spending increased with active utilization. It will be beneficial for future studies to analyze the long-term effects of the remote diabetes management program and assess impacts on patient health and well-being.

Overview

CoChat Summary

TL;DR

A retrospective analysis of a remote digital diabetes management program (Livongo) among employees of three self-insured employers found that program access was associated with a 21.9% decrease in medical spending, translating to $88 per member per month at 1 year. Lower mean blood glucose values were also associated with lower medical spending.

Key findings

  • Program access was associated with a 21.9% (p < 0.01) decrease in medical spending, translating into an $88.21 per member per month saving at 1 year; this was driven by a 10.7% (p < 0.01) reduction in diabetes-related spending and a 24.6% (p < 0.01) reduction in office-based services spending.
  • Each additional day of Livongo membership was associated with a 0.11% (p < 0.01) decline in medical spending; in subpopulations with >90 or >180 days of membership, the treatment effect on medical spending was −24.2% (p < 0.01) and −25.8% (p < 0.01), respectively.
  • Member-months with mean BG ≤ 154 mg/dL had significantly lower total costs ($561.66 vs $715.50 pmpm, p = 0.03), diabetes-related costs ($246.32 vs $393.93 pmpm, p = 0.007), and inpatient costs ($131.46 vs $271.77 pmpm, p = 0.02) than those with mean BG > 154 mg/dL.
  • Instrumental variables results were similar: program access was associated with a 12.1% (p < 0.01) reduction in total medical spending, and each additional day per month of active use was associated with a 5.1% (p < 0.01) reduction.

Methods

  • Retrospective analysis of medical claims and remotely captured blood glucose data from the Livongo for Diabetes program, including 2,261 members and 8,741 non-members with diabetes from three self-insured employers, continuously enrolled for 12 months before and after program access (June 2014–January 2018).
  • Multivariable difference-in-difference regression models with patient fixed effects and Charlson comorbidity index controls, using binary and continuous treatment definitions; instrumental variables (two-stage least squares) using employer launch date as the instrument, with propensity score matching in the appendix; standard errors clustered at the individual level.
  • Medical spending outcomes came from claims; blood glucose control was categorized as mean BG ≤ 154 mg/dL or > 154 mg/dL, described as equivalent to an ADA target HbA1c of 7.0%.

Limitations

  • The paper states it only examines short-term (1-year) effects; long-term effects on spending, patient health, and well-being remain unknown and may be larger.
  • The paper states the study is non-randomized: members had higher baseline comorbidity (Charlson index 1.61 vs 1.09, p < 0.01) and higher baseline monthly spending ($612 vs $554, p = 0.04), and unmeasured confounders could exist; instrumental variables were used to partly address this.
  • The paper notes that pharmacy spending, non-reimbursed care, and the employer’s cost of the Livongo program were not included in the spending outcomes; future work is needed in under-insured, Medicare, and Medicaid populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/13696998.2019.1609483

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 11 Not checked · 79 Own results and interpretations

50 more claims

Create a free account to see all 90 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 17 references

Research works printed but not linked: 5

  1. Centers for Disease Control and Prevention, 2017, National Diabetes Statistics Report
  2. Jones PJ, 2011, RAND Corporation
  3. Downing J, 2017, JMIR, 19, e234
  4. Halvorsen R, 1980, Am Econ Rev, 70, 474
  5. Duru OK, 2010, Am J Manag Care, 16, 33

Cited by

See all 49

Metadata

Authors
Whaley, C. M., Bollyky, J. B., Lu, W., Painter, S., Schneider, J., Zhao, Z., He, X., Johnson, J., & Meadows, E. S.
Affiliations
  • RAND Corporation (US)
  • Livongo Health, Mountain View, CA, USA;
  • Eli Lilly (United States) (US)
Corresponding author
Painter, Stefanie
Venue
Journal of Medical Economics
Published
2019-05-08
Volume
22
Issue
9
Pages
869-877
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W2941605630
Cited by
49
References
17
Citations by year
2026: 2 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 4
FWCI
9.19
Type
journal article
Language
en
Open access
Locations
  • Journal of Medical Economics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
digital health technologies, health care costs, glycemic control, telemedicine, employer-sponsored health insurance, cost reduction
MeSH terms
Self-Management, Wearable Electronic Devices, Adolescent, Adult, Blood Glucose, Child, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Health Expenditures, Female, Health Resources, Health Services, Humans, Insurance Claim Review, Male, Middle Aged, Retrospective Studies, Blood Glucose Self-Monitoring, Telemedicine, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values. https://app.cochat.ai/papers/10.1080/13696998.2019.1609483
The paper
Whaley, C. M., Bollyky, J. B., Lu, W., Painter, S., Schneider, J., Zhao, Z., He, X., Johnson, J., & Meadows, E. S. (2019). Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values. Journal of Medical Economics. https://doi.org/10.1080/13696998.2019.1609483

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.